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Abstract
Background: In addition to clinical characteristics, DNA aneuploidy has been identified as a prognostic factor in
epithelial malignancies in general and in endometrial cancers in particular. We mapped ploidy-associated
chromosomal aberrations and identified corresponding gene and protein expression changes in endometrial
cancers of different prognostic subgroups.
Methods: DNA image cytometry classified 25 endometrioid cancers to be either diploid (n = 16) or aneuploid (n =
9), and all uterine papillary serous cancers (UPSC) to be aneuploid (n = 8). All samples were subjected to
comparative genomic hybridization and gene expression profiling. Identified genes were subjected to Ingenuity
pathway analysis (IPA) and were correlated to protein expression changes.
Results: Comparative genomic hybridization revealed ploidy-associated specific, recurrent genomic imbalances.
Gene expression analysis identified 54 genes between diploid and aneuploid endometrioid carcinomas, 39 genes
between aneuploid endometrioid cancer and UPSC, and 76 genes between diploid endometrioid and aneuploid
UPSC to be differentially expressed. Protein profiling identified AKR7A2 and ANXA2 to show translational alterations
consistent with the transcriptional changes. The majority of differentially expressed genes and proteins belonged to
identical molecular functions, foremost Cancer, Cell Death, and Cellular Assembly and Organization.
Conclusions: We conclude that the grade of genomic instability rather than the histopathological subtype
correlates with specific gene and protein expression changes. The identified genes and proteins might be useful as
molecular targets for improved diagnostic and therapeutic intervention and merit prospective validation.
Keywords: aneuploidy, endometrial carcinoma, genomic instability, comparative genomic hybridization, expression
arrays, pathway analysis, UPSC
Background
Endometrial cancer is the most common malignancy of
the female genital tract in the Western world and the
fourth common cancer in women [1]. In general it is
considered to have a favorable prognosis since it usually
becomes symptomatic at an early tumor stage. Thus,
about 70% of the affected women are detected at tumor
stage I. At this stage, the mean survival of five years has
been estimated to be 87%. However, one
histopathological subtype, uterine papillary serous can-
cer (UPSC), presents with an aggressive clinical course
characterized by early metastasis, reduced survival rates
and inferior prognosis compared to endometrioid carci-
nomas [2]. Next to histopathology, tumor stage and
tumor grade are known to be the most influencing
prognostic factors [3].
In breast, prostate and colorectal cancer, also DNA
aneuploidy has been reported to be an independent
prognostic marker [4-6]. In endometrial cancer, patients
with diploid cell populations have a more favorable 5-
year survival rate of 94% as opposed to those with aneu-
ploid malignancies (83%) [7]. Aneuploidy can be
assessed at the chromosomal level by comparative
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results have shown a conserved pattern of chromosomal
gains and losses that is distinct and characteristic for
different epithelial malignancies [9]. In carcinomas of
the vagina the most frequent aberration detected is a
gain of 3q [10], while in endometrial carcinomas, copy
number gains were mapped to chromosome arms 1q,
3q, 8q, and 10q [11-13]. The predominance of these
tumor entity specific chromosomal alterations leads to
increased expression of resident genes that seems to be
independent of tissue and/or cell type [14] and gives an
irreversible disturbance of transcriptional regulation in
aneuploid cells [15].
Against this background we now evaluated whether
genomic instability correlates with chromosomal altera-
t i o n sa n di m p a c t so ng e n ea n dp r o t e i ne x p r e s s i o n
changes in endometrial carcinomas. We utilized well-
characterized surgical specimens of endometrial cancer
representing different histopathological subtypes which
are associated with a distinct prognosis (Figure 1).
Figure 1 Technical workflow of the study design. * No protein was identified in the EnA vs. UPSC-A comparison due to extremely weak
abundance of the protein spot in the polyacrylamide gel.
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Here we describe a comprehensive evaluation of aneu-
ploidy-associated alterations of the genome, transcrip-
tome, and proteome in different histopathological
subtypes of endometrial cancer. We were particularly
interested in identifying chromosomal alterations that
underlay aneuploidy and how these might impact on
transcriptional and translational changes and thereby
influence patients’ prognosis.
Genomic instability
Of the cancerous samples, 16 of the 25 endometrioid car-
cinomas showed diploid cell distribution pattern (EnD)
and nine presented with aneuploid cell populations (EnA),
while all eight UPSC tumors were classified as aneuploid
(UPSC-A). Representative histograms for each group are
provided in Figure 2. The mean value of the DNA stem
line increased from 2.23c in the EnD group to 2.98c in the
EnA and 3.06c in the UPSC-A group (p < 0.004).
The “stemline scatter index” (SSI) measures the clonal
heterogeneity of the constituent tumor cells and is cal-
culated as the sum of (a) the percentage of cells with
DNA content values in the S-phase region (S-phase), (b)
the percentage of cells with DNA content values exceed-
ing twice the modal value plus 1c (G2 exceeding rate),
and (c) the coefficient of variation (CV) of the respective
tumor stemline [16]. In our study, all but one diploid
and all aneuploid carcinomas showed SSI values above
the threshold of overall genomic instability (of 8.8)
found for breast carcinomas [16]. The mean SSI values
of 26.9 (EnD), 45.4 (EnA), and 53.5 (UPSC-A) now
found indicate increasing genomic instability for aneu-
ploid and UPSC subtypes (p < 0.004). The increasing
degree of genomic instability in the EnA and UPSC-A
groups compared to the EnD group was also reflected in
an increase in chromosomal copy number changes as
measured by CGH. A detailed summary and comparison
of chromosomal aberrations found is presented in Fig-
ure 2. Chromosomal imbalances in the EnD tumors
were mostly restricted to gains of chromosome 1q (33%)
and 16p (11%). In contrast, EnA tumors showed diverse
changes, including a gain of 10q, 20q (both 33%), and
1q, 8q, 10p, 16p and 17q (all 22%). These changes were
accompanied by frequent losses of 9q, 16q, 17p, 19p,
19q and 22q (all 22%) (Additional file 1). In the UPSC-
A malignancies, chromosomal aberrations affected also
chromosomal regions that were not changed in the
endometrioid tumors. UPSCs presented in 62% a gain of
2q, 8q, 17q, and 20p and in 50% a gain of 20q. The
most frequent loss was observed for 15q (50%).
The increasing number of chromosomal aberrations
between the EnD and EnA carcinomas and between the
EnA and UPSC-A malignancies was furthermore reflected
by the average number of copy number alterations
Figure 2 Examples of ploidy types and number of differential expressed genes (DEGs) and proteins (DEPs). DNA histograms show DNA
content on the x-axis and the total number of cell on the y-axis.
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mal aberrations and divided by the number of cases ana-
lyzed. The ANCA value increased from 0.041 (EnD) to
0.145 (EnA) and up to 0.429 (UPSC-A) (p < 0.001). The
same trend was found for the average number of regional
amplifications (ANRA, calculated as the sum of all amplifi-
cations and divided by the number of cases analyzed). The
ANRA amounted to 0.003 in the EnD group, increased to
0.014 in the EnA group and to 0.065 in the UPSC-A
group (p < 0.002).
Gene expression profiling
We applied the Wilcoxon test with permutation test and
the stepwise algorithm [17] to identify differentially
expressed genes for pair-wise comparisons of the three
groups. Considering only those genes that were commonly
detected by both approaches, we found that 54 genes were
differentially expressed between EnD and EnA samples. A
total of 39 differentially expressed genes (DEGs) defined
expression differences between the aneuploid malignancies
of endometrioid or UPSC histology (EnA and UPSC-A).
However, the vast majority-76 genes-was differentially
expressed between the groups distinguished by different
histology and ploidy status, namely EnD and UPSC-A
(Table 1). All genes were unique for pair-wise group com-
parison. The gene lists describing differences between all
groups are listed in Additional file 2.
When mapping the differentially expressed genes to
their chromosomal location, we found that the deregula-
tion of 114 out of 275 (41.45%) genes could be attribu-
ted to chromosomal copy number changes.
Correlation of Gene and Protein expression changes
Mapping differentially expressed proteins (DEPs) pre-
viously detected by two-dimensional gel electrophoresis
[18] to the chromosomal location of their corresponding
g e n e ss h o w e dt h a ti nt h eE n Dv e r s u sE n Ac o m p a r i s o n
11 of 20 proteins (55%) and in the EnD versus UPSC-A
comparison 7 of 15 (47%) mapped to positions that
were affected by copy number changes (Additional file
3).
For 5 of the 35 identified proteins, the corresponding
cDNA was included on our microarray platform. Two
of the corresponding genes, AKR7A2 and ANXA2,
showed a similar trend in transcriptional expression as
observed for the translational changes. However, both
genes did not reach our significance levels of the gene
expression analysis: AKR7A2 was down-regulated in
EnD versus UPSC-A, while ANXA2 showed an up-regu-
lation in EnA versus EnD and in UPSC-A versus EnD.
Functional annotation of DEGs and DEPs that discern the
EnD, EnA, and UPSC-A tumors using Ingenuity Pathway
Analysis
Using Ingenuity Pathway Analysis (IPA), differentially
expressed genes and proteins that discerned EnD, EnA,
and UPSC-A were functionally annotated. An overview
of all networks found by transcriptomic and proteomic
profiling is provided in Table 2.
For the comparison of EnD versus EnA, 45 (83%) of
the 54 DEGs were recognized in the IPA database and
resulted in three networks. The highest ranked network
with a score of 48 comprised 20 of the DEGs. These
genes interacted in a network (Figure 3a) associated
with Lipid Metabolism, Small Molecule Biochemistry,
and Vitamin and Mineral Metabolism.N F k B ,J n ka n d
ERK1/2 were central nodes of this network and asso-
ciated with diseases and functions regarding Cancer,
Hematological Disease,a n dGastrointestional Disease (p
< 0.00001 to p < 0.0161). The second highest network
(score of 30) comprised 14 of the DEGs and was asso-
ciated with Lipid Metabolism, Small Molecule Biochem-
istry,a n dGenetic Disorder. The third network (score of
22) comprised 11 of the DEGs and was associated with
Gene Expression, Nutritional Disease and Cellular
Development.
The comparison between the aneuploid carcinomas
(EnA versus UPSC-A) allowed 33 (84.6%) of all 39
DEGs for IPA analysis. Three overlapping networks
reached the level of significance, with a score of 28 to
22. The top network (score of 28) was associated with
Cardiovascular System Development and Function, Cell
Cycle, Lipid Metabolism and particularly with the cano-
nical pathways Gene Expression (p < 0.0245) and Cell
Death (p < 0.0338). This network interacts via BIRC2,
SAA, and SAA1 with the second highest network (score
of 28), associated with Cell Death, Cellular Movement,
and Haematological System Development and Function,
a n dv i aC T S H ,I T P R 2 ,a n dS A A 1w i t ht h et h i r dh i g h e s t
Table 1 Overview of significantly expressed genes
Wicoxon test (p < 0.05)
EnD versus EnA EnD versus UPSC-A EnA versus UPSC-A
478 576 276
Stepwise Analysis (Up/Down)
EnD versus EnA EnD versus UPSC-A EnA versus UPSC-A
140/118 195/179 165/154
Genes present in both analyses
EnD versus EnA EnD versus UPSC-A EnA versus UPSC-A
90 117 68
Genes unique for each group comparison
EnD versus EnA EnD versus UPSC-A EnA versus UPSC-A
54 76 39
EnD, endometrioid diploid
EnA, endometrioid aneuploid
UPSC-A, UPSC aneuploid
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Comparison Analysis Top networks Score Top Diseases
and Disorders
p-Value # of
Molecules
Top
Molecular
and Cellular
Functions
p-Value # of
Molecules
EnD vs. EnA Transcriptomics Lipid Metabolism, Small
Molecule Biochemistry,
Vitamin and Mineral
Metabolism
48 Cancer < 0.0161 23 Lipid
Metabolism
< 0.0184 6
Lipid Metabolism, Small
Molecule Biochemistry,
Genetic Disorder
30 Hematological
Disease
< 0.0132 12 Small
Molecule
Biochemistry
< 0.0184 10
Gene Expression, Nutritional
Disease, Cellular Development
22 Gastrointestinal
Disease
< 0.0105 9 Vitamin and
Mineral
Metabolism
< 0.0175 12
Proteomics
& Cellular Assembly and
Organization, Nucleic Acid
Metabolism, Small Molecule
Biochemistry
25 Neurological
Disease
< 0.0106 7 Cellular
Growth and
Proliferation
< 0.0382 7
Genetic
Disorder
< 0.0486 8 Cell
Morphology
< 0.0297 4
Cancer < 0.0394 7 Cellular
Assembly
and
Organization
< 0.0346 6
EnD vs.
UPSC-A
Transcriptomics Organism Injury and
Abnormalities, Cardiac
Necrosis/Cell Death, Cell
Death*
44 Cancer < 0.0196 31 Cellular
Growth and
Proliferation
< 0.0212 28
Organ Morphology,
Reproductive System
Development and Function,
Skeletal and Muscular
Disorders
#
28 Genetic
Disorder
< 0.0234 47 Cell-To-Cell
Signaling and
Interaction
< 0.0234 11
Cellular Development, Cellular
Growth and Proliferation,
Cancer
20 Reproductive
System Disease
< 0.0196 12 Cell Death < 0.0234 26
Cardiovascular Disease,
Hematological Disease,
Skeletal and Muscular
Disorders
19
Endocrine System
Development and Function,
Small Molecule Biochemistry,
Gene Expression
15
Proteomics
& Lipid Metabolism, Small
Molecule Biochemistry, Cell
Morphology *,
#
25 Cancer < 0.0428 7 Amino Acid
Metabolism
< 0.0150 2
Gastrointestinal
Disease
< 0.0214 4 Cell
Morphology
< 0.010 1
Inflammatory
Disease
< 0.0479 2 Cellular
Assembly
and
Organization
< 0.0125 2
EnA vs.
UPSC-A
Transcriptomics Cardiovascular System
Development and Function,
Cell Cycle, Lipid Metabolism
28 Cardiovascular
Disease
< 0.0430 12 Gene
Expression
< 0.0245 7
Cell Death, Cellular
Movement, Hematological
System Development and
Function
28 Development
Disorder
< 0.0301 5 Cell Death < 0.0338 15
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Page 5 of 12network (score of 22), associated with Cellular Assembly
and Organization, Cellular Function and Maintenance,
and Cell Signalling) (Figure 3b). Interestingly, SAA1
connected as well network 2 and network 3 with each
other. IFNG, TGFB, MYC, and NFkB act as central
nodes in these networks.
In comparisons of EnD versus UPSC-A, a total of 67
(88.2%) of the 76 DEGs were part of the IPA database.
Here, we could define five overlapping networks with
t h ef i r s to n er e a c h i n gas c o r eo f4 4i n c l u d i n g2 0o ft h e
DEGs being associated with pathways of Organismal
Injury and Abnormalities, Cardiac Necrosis/Cell Death,
and Cell Death. Network 2 obtained a score of 28, com-
prised 14 DEGs and revealed Organ Morphology, Repro-
ductive System Development and Function,a n dSkeletal
and Muscular Disorders pathways. The third network
reached a score of 20, comprised 11 of the DEGs and
was associated with Cellular Development, Cellular
Growth and Proliferation,a n dCancer. The fourth high-
est ranked network reached a score of 19, comprised 11
of the DEGs and was associated with Cardiovascular
Disease, Hematological Disease, and Skeletal and Muscu-
lar Disorders. The fifth network consists of 9 DEGs and
reached a score of 15. Associated network functions
were Endocrine System Development and Function,
Small Molecule Biochemistry,a n dGene Expression.A l l
networks were associated with Cancer (p < 0.0196),
Genetic Disorder (p < 0.0234), Cellular Growth and Pro-
liferation (p < 0.0212), and Cell-To-Cell Signalling and
Interaction (p < 0.0234). Three remaining networks
obtained one focus gene only and failed the level of sig-
nificance with a score < 5. Involved genes of all net-
works are presented in Additional file 4.
A network comparison analysis between all significant
networks mentioned above and their corresponding pro-
tein profiling networks showed three interacting net-
works connected via ACTB and PDGFBB (Table 2),
thus representing a close relation of transcriptomics and
proteomics data.
Discussion
We mapped ploidy-associated chromosomal aberrations
a n di d e n t i f i e dc o r r e s p o n d i n gg e n ea n dp r o t e i n
expression changes in endometrial cancers of different
prognostic subgroups, including diploid (n = 16) and
aneuploid (n = 9) endometrioid, and aneuploid uterine
papillary serous cancer (n = 8) malignancies. CGH
revealed ploidy-associated specific, recurrent genomic
imbalances comprising gains of chromosome arms 1q,
3q, and 8q, as well as losses of 4q and 15q. Since these
alterations dominate recurrent pattern of chromosomal
imbalances characterizing endometrial malignancies, the
genes located on such aberrant chromosome loci might
play a key role in initiation and/or progression of endo-
metrial malignancies.
The identified genes with altered expression changes
belong to several functional groups. These genes are
involved in functions related to fundamental biological
processes known to be affected in cancer. For instance,
ATF3, DNMT3B, LMo2,a n dTCF12 affect DNA bind-
ing, transcriptional activation and proliferation. Interest-
ingly, a higher proliferation rate of aneuploid as
compared to diploid endometrial carcinomas has been
observed [19].
Another group includes genes that code for enzymatic
proteins like proteases, reductases, and transferases.
Many of these genes, such as aflatoxin B 1 aldehyde
reductase member 2 (AKR7A2), v-yes-1 Yamaguchi sar-
coma viral related oncogene homolog (LYN), or cyto-
chrome b reductase 1 (CYP1B1) have not been reported
in prior studies of endometrial cancer and thus provide
novel potential targets for diagnosis and treatment.
AKR7A2 (located at 1p36.13) is a Golgi-associated
AKR7 family member and is expressed in a broad range
of tissues [20]. AKR7A2 is involved in the detoxification
of aldehydes and ketones in the phase I metabolism.
AKR7A2 protein levels are elevated in the cerebral cor-
tex of patients with Alzheimer disease [21]. Our results
of the expression analysis indeed proved the proteomic
data that demonstrate an AKR7A2 overexpression in
EnD compared to UPSC-A [18]. LYN (located at 8q13)
is among the highly ranked signature genes overex-
pressed in EnD versus EnA carcinomas and documents
a strong correlation between DNA and RNA analysis.
LYN is a member of the Src-family kinases, a family of
non-receptor tyrosine kinases. LYN was of particular
Table 2 IPA analysis overview (Continued)
Cellular Assembly and
Organization, Cellular
Function and Maintenance,
Cell Signaling
22 Connective
Tissue Disorder
< 0.0487 9 Cellular
Movement
< 0.0485 8
& Refers to Gemoll et al. [18]
* Overlapping of marked networks via platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog) dimer (PDGFBB)
# Overlapping of marked networks via beta-Actin (ACTB)
EnD, endometrioid diploid
EnA, endometrioid aneuploid
UPSC-A, UPSC aneuploid
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Page 6 of 12Figure 3 IPA-based pathway analysis of differential expressed genes. (a) Red and green designations indicate over- and underexpressed
genes in the respective groups. Blue arrows and circulations indicate central nodes of the networks. (b) Red and green designations indicate
over- and underexpressed genes in the respective groups. Blue arrows and circulations indicate central nodes of the networks.
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Page 7 of 12interest because as a kinase, it is “druggable” and might
provide a therapeutic opportunity for targeting endome-
trial cancer. Choi et al. identified LYN as a possible new
therapeutic target with particular relevance to clinically
aggressive basal-like breast cancer [22].
A further group consists of genes and proteins
involved in mechanisms of transport and protein bind-
ing. Annexins are characterized by their capacity to bind
to phospholipids in the presence of calcium ions and
their susceptibility to phosphorylation and dephosphory-
lation. Belonging to subfamily A of annexins, human
annexins are further classified as annexin A1-A11 and
A13. One isoform, ANXA2 (Annexin A2; located at
15q22.2) was found significantly upregulated as detected
in our proteomic approach and proved the same trend
with respect to gene expression [18]. ANXA2 is located
in the cytoplasm as a monomer (heavy chain of 36 kDa,
or p36) or in a complex with a member of the S100A10
[23]. There is evidence of a relationship between pro-
teases and extracellular matrix (ECM) proteins through
ANXA2 whereby ANXA2 may facilitate the reorganiza-
tion of the ECM in physiological and pathological pro-
cesses such as tumor invasion [24]. Therefore, the over-
expression of ANXA2 in colorectal and gastric carcino-
mas alludes to a correlation with invasiveness and poor
prognosis and is in line with our analysis [25,26].
Further, we found Wnt-7a (wingless-type MMTV inte-
gration site family, member 7A; located at 3p25) to be
more expressed in EnA samples compared to EnD can-
cers. Wnt genes are associated with cellular responses
such as proliferation, cell fate determination or specifi-
cation, apoptosis and oncogenesis. The Wnt-7a gene is
detected at high levels in the female reproductive tract
[27]. Observations suggest that disruption of normal
Wnt-7a expression by diethylstilbestrol and other estro-
genic compounds leads to altered uterine cytoarchitec-
ture and might be a mechanism ultimately causing
neoplasia in the reproductive tract [28].
In the comparison of EnD and UPSC-A cases we
found that the progesterone receptor (PGR; located at
11q22-q23) gene was significantly lower expressed in
UPSC-A cases. PGR showed the highest ratio of differ-
ential expression overall. Furthermore, lower expression
in UPSC-A was associated with a loss of the whole
chromosome 11 in 25% of the UPSC-A cases whereas in
diploid cases no alteration could be detected. PGR
encodes a member of the steroid receptor superfamily.
The encoded protein mediates the physiological effects
of progesterone, which plays a central role in reproduc-
tive events associated with the establishment and main-
tenance of pregnancy. Excessive estrogen stimulation,
unbalanced by progesterone, might play a central role in
the development of endometrial cancer across all ethnic
populations [29,30]. Progesterone ameliorates estrogen-
induced proliferation by interacting with its receptor
[31,32], primarily through two functionally distinct PGR
isoforms. It could be shown that hormone therapy of
PGR-positive patients increases their response rate sub-
stantially from 8-17% to 37-89% [33]. Our data exhibit
that particularly patients with diploid carcinomas could
benefit from hormone therapy and that ploidy status
assessment could assist in patient stratification.
The comparison between EnA and UPSC-A revealed
one network including the differentially expressed genes
BIRC2 (baculoviral IAP repeat-containing 2; located at
11q22), BIRC3 (baculoviral IAP repeat-containing 3;
located at 11q22), MAP3K5 (mitogen-activated protein
kinase kinase kinase 5; located at 6q22.33), and SAA1
(serum amyloid A1, located at 11p15.1). All four genes
are associated with different cancer types in general but
a connection to endometrial cancer has not been
described so far. Interestingly, all four genes are lower
expressed in the UPSC-A cancers. These findings are in
accordance with a loss of the according gene loci on
chromosome 6 and 11 in up to 25% of the UPSC-A
cases whereas in the EnA cases no alteration could be
detected. BIRC2 and BIRC3 are members of a family of
proteins that inhibit apoptosis by binding to tumor
necrosis factor receptor-associated factors TRAF1 and
TRAF2, probably by interfering with activation of ICE-
like proteases. These encoded proteins inhibit apoptosis
induced by serum deprivation and menadione, a potent
inducer of free radicals. Cheng et al. showed that BIRC2
overexpression might play a critical role for mammary
carcinogenesis associated with p53 mutations [34]. It is
of interest that overexpression of BIRC2 has been
recently proposed to be associated with luminal subtype
B of breast cancer [35]. MAP3K5 (also known as apop-
tosis signal-regulating kinase 1; ASK1) has been widely
accepted as one of the key components regulating reac-
tive oxygen species (ROS) [36]. There is evidence sug-
gesting that oxidative stress contributes to the
pathogenesis of prostate cancer [37]. SAA1, a high-den-
sity lipoprotein (HDL)-associated apolipoprotein, is an
acute-phase protein which is elevated in response to
trauma, inflammation, and neoplasia [38]. SAA1 has
several functions such as tumor cell invasion and metas-
tasis by induction of cell adhesion and migration
through induction of enzymes degrading the ECM and
inhibition of cell attachment to ECM proteins by SAA
derived peptides [39-41]. Cumulatively, these properties
might place SAA as an ECM-associated adhesion pro-
tein, with a potential role in tumor pathogenesis.
Conclusions
We detected that chromosomal copy number alterations
do impact on gene expression changes. In addition, dif-
ferentially expressed genes and proteins interacted
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further by two differentially expressed proteins,
AKR7A2 and ANXA2, showing similar gene expression
alterations. Overall, we have identified different and spe-
cific expressions patterns between 16 diploid endome-
trioid-, 9 aneuploid endometrioid-cancers, and 8
aneuploid UPSCs with CGH, RNA microarray and two-
dimensional gel electrophoresis. We have revealed a
number of aberrantly regulated genes and proteins that
are potential biomarkers for an improved diagnosis and
prognostication in endometrial cancers.
Methods
Patient Samples
Fresh tumor material was collected from women who
underwent hysterectomy for endometrial cancer at the
Department of Obstetrics and Gynecology at the Kar-
olinska University Hospital, Stockholm, Sweden, dur-
ing 1997 and 2003. Clinical material was collected
from surgically removed tumors adhering to the
approval of the local ethical review board. Carcinomas
were diagnosed on H&E-stained tissue sections and
graded according to the FIGO classification [42].
Patients treated with neoadjuvant therapy were
excluded. A total of 25 endometrioid carcinomas and
8 UPSCs were randomly selected for ploidy assess-
ment as well as genomic, and transcriptomic analysis.
Proteomic analysis of according samples was reported
earlier [18]. Data on ploidy, histopathologic subtype,
stage, age, observation time, and survival status are
provided in Table 3. After surgery, clinical tissues
were first used for touch preparation slides for ploidy
assessment and then snap frozen until further proces-
sing. Snap frozen specimens were divided into one
part for protein expression and one part for DNA and
RNA extraction. In addition, paraffin-embedded speci-
m e n so ft h es a m et u m o r sw e r eu s e df o rh i s t o p a t h o l -
ogy and immunohistochemistry.
Image Cytometry
Image cytometry was performed on Feulgen-stained
paraffin-embedded histopathological slides. The
staining procedure, internal standardization, and
tumor cell selection were based on methods
described previously [4]. All DNA-values were
expressed in relation to the corresponding staining
controls which were given the value 2c, denoting the
normal diploid DNA-content. The tumors were clas-
sified as belonging to three groups: (i) diploid cases
with a distinct peak in the normal 2c region and no
cells exceeding 5c, (ii) aneuploid cases with a main
peak different from 2c and a stemline scatter index
(SSI) below or equal 8.8, and (iii) aneuploid samples
with a varying numbers of cells (> 5%) exceeding 5c
(SSI above 8.8). This novel classification system
adheres to the parameters established by Kronenwett
and colleagues, who defined the stemline scatter
index (SSI) as a measurement of clonal heterogeneity
in the tumor cell population [16].
The degree of genomic instability status in the three
groups (EnD, EnA, UPSC-A) was compared with metric
parameters (stemline, SSI, ANCA, ANRA) using
ANOVA test. The threshold of significance was set to p
< 0.05.
Comparative Genomic Hybridization (CGH)
DNA was extracted from fresh frozen tissue using TRI-
zol. CGH was performed as described in detail http://
www.riedlab.nci.nih.gov. Fluorescence intensity ratio
plots were generated using Leica CW4000 Karyo V1.0
software (Leica Imaging Systems, Cambridge, UK).
Interpretation of changes at 1pter, 16, 19, and 22
required careful examination because these loci are
prone to artifacts due to the high proportion of repeti-
tive sequences. CGH profiles of individual cases as well
as the summary display of all cases can be found at
http://www.ncbi.nlm.nih.gov/sky/skyweb.cgi.
Microarray analysis
Total RNA was extracted using TRIzol (Invitrogen) fol-
lowed by Qiagen RNeasy column purification (Qiagen,
Valencia, CA). All samples were hybridized against the
universal human reference RNA (Stratagene, La Jolla,
CA, USA) using a slightly modified protocol from
Hedge and colleagues [43]. Extraction and hybridization
protocols used can be viewed in detail at http://www.rie-
dlab.nci.nih.gov.
In brief, 20 μg of total RNA was reverse transcribed
using random primers and converted into cDNA using
reverse transcriptase. After incorporation of aminoallyl-
conjugated nucleotides, the RNA was indirectly labelled
with Cy3 (tumor RNA) and Cy5 (reference RNA, Amer-
sham, Piscataway, NJ). Each sample was hybridized
against the reference RNA in a humid chamber
(Arraylt™ Hybridization Cassette, TeleChem Intl., Sun-
nyvale, CA, USA) for 16 hours at 42°C, washed, and
scanned by the Axon GenePix 4000B Scanner (Axon
Instruments, Union City, CA, USA). In order to account
for potential amplification bias, total RNA was hybri-
dized following the same protocol for 11 samples (20 μg
each). We used customized arrays obtained from the
National Cancer Institute’s microarray core facility.
Arrays were used from one print batch and composed
of 9, 128 cDNAs denatured and immobilized on a poly-
L-lysine-coated glass surface. The gene annotation file
(GAL file) used (Hs-UniGEM2-v2px-32Bx18Cx18R.gal)
can be found at the facility’s website http://nciarray.nci.
nih.gov. GenePix software version 4.0.1.17 was used to
Habermann et al. Molecular Cancer 2011, 10:132
http://www.molecular-cancer.com/content/10/1/132
Page 9 of 12apply the GAL file through an interactive gridding pro-
cess. All images of the scanned microarray slides were
meticulously inspected for artifacts. Empty spots and
aberrant spots and slide regions were flagged for exclu-
sion from analyses [44].
Microarray quality assessment and data analysis (two-
group class comparison)
After discarding arrays that did not pass our visual
quality filtering, a total of 13 EnD, 9 EnA, and 7
UPSC-A malignancies could be processed for further
analysis. All values that did not meet the quality con-
trol criteria were treated as missing values as described
in supplemental materials (Additional file 5). Intensity
ratios were calculated using the background corrected
median intensities that were normalized with the
locally weighted scatter plot smoother (LOWESS) algo-
rithm for each print-tip group. The fraction of data
points used in the local regression (f)w a s0 . 2a n d
other parameters were adjusted as suggested by Cleve-
land [45]. The value of f was determined using self ver-
sus self experiment. All within-slide normalized ratios
Table 3 Clinical data and ploidy assessment
Case Histo-
pathology
Ploidy SSI Age FIGO
1988
FIGO
2010
Grade Metastasis CGH ANCA ANRA Observation
time
Died at
month
D01 endometrioid diploid 35, 0 83 1c 1b 1 no 3191 0.043 0 74
D02 endometrioid diploid 31, 7 59 1b 1a 1 no 3192 0.087 0 42 42
D03 endometrioid diploid 45, 3 60 1c 1b 1 no 3193 0.130 0 94
D04 endometrioid diploid 16, 1 52 1b 1a 1 no 3194 0 0 92
D05 endometrioid diploid 6, 8 87 1c 1b 2 no 3195 0.043 0.043 15 15
D06* endometrioid diploid 13, 2 67 1b 1a 2 no 3196 0.043 0 109
D07* endometrioid diploid 17, 6 78 3a 3a 2 yes 3197 0.174 0 4 4
D08* endometrioid diploid 13, 7 78 1b 1a 1 no 3198 0.043 0 104
D09 endometrioid diploid 17, 3 59 1b 1a 1 no 3193 0 0 94
D10 endometrioid diploid 12, 4 55 1b 1a 1 no 3200 0 0 94
D11 endometrioid diploid 14, 5 81 1b 1a 1 no 3201 0 0 86
D12 endometrioid diploid 46, 5 72 1b 1a 1 no 3202 0 0 75
D13 endometrioid diploid 35, 6 63 1c 1b 2 no 3203 0 0 26 26
D14 endometrioid diploid 56, 4 51 1b 1a 1 no 3204 0 0 88
D15 endometrioid diploid 31, 0 53 1b 1a 2 no 3205 0 0 55
D16 endometrioid diploid 38, 4 66 1b 1a 3 no 3206 0.087 0 53
Ae1 endometrioid aneuploid 68, 0 82 1c 1b 1 no 3207 0.043 0 146
Ae2 endometrioid aneuploid 20, 4 80 1b 1a 1 no 3208 0.304 0 71
Ae3 endometrioid aneuploid 35, 2 69 1b 1a 1 no 3203 0.043 0 107
Ae4 endometrioid aneuploid 26, 9 46 1b 1a 2 no 3210 0.565 0.087 81
Ae5 endometrioid aneuploid 35, 5 55 2a 2 3 yes 3211 0.087 0 73
Ae6 endometrioid aneuploid 30, 7 66 1b 1a 2 no 3212 0 0 63
Ae7 endometrioid aneuploid 71, 0 79 1b 1a 2 no 3213 0.130 0.043 55
Ae8 endometrioid aneuploid 59, 6 60 1b 1a 3 no 3214 0.043 0 51
Ae9 endometrioid aneuploid 61, 7 72 1c 1b 3 yes 5521 0.087 0 42
Au1 UPSC aneuploid 70, 9 77 3a 3a 3 yes 3215 0.565 0.174 36 36
Au2 UPSC aneuploid 42, 0 78 4b 4b 0 yes 3216 0.609 0 51
Au3 UPSC aneuploid 28, 5 66 1c 1b 3 no 3217 0.652 0.043 19 19
Au4 UPSC aneuploid 59, 7 80 3a 3a 3 yes 3218 0.565 0 27 27
Au5 UPSC aneuploid 48, 6 90 3 3a 3 yes 3219 0.130 0 9 9
Au6 UPSC aneuploid 27, 5 88 3b 3b 0 yes 3220 0.478 0.13 17 17
Au7* UPSC aneuploid 59, 2 80 1a 1a 0 no 3359 0.348 0.13 7 7
Au8 UPSC aneuploid 91, 3 83 3a 3a 0 yes 5522 0.087 0.043 10 10
* Arrays did not pass visual quality criteria and were thus excluded from further analysis.
Staging was assessed according to FIGO Committee on Gynecologic Oncology. Ploidy status was defined by image cytometry according to the Auer classification.
Observation time is given in months. For CGH, the case number of the database is given http://www.ncbi.nlm.nih.gov/sky/skyweb.cgi. SSI, Stem line scatter index.
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Page 10 of 12were log-transformed (natural base). A total of 4, 995
genes were identified that did not show any missing
values across all samples. Out of those 4, 995 genes,
differentially expressed genes were identified with pair-
wise analysis. To identify differentially expressed genes
we used Wilcoxon rank-sum test with a permutation
test (p < 0.05) and a step-wise gene selection proce-
dure [17,46]. Genes that were identified by both
approaches were selected for further analysis. Further
details of applied algorithms can be found in Addi-
tional file 6.
Biological pathway analysis
We used IPA software (v8.7, Ingenuity, Mountain View,
CA) to assess the involvement of significantly differen-
tially expressed genes and proteins in known pathways
and networks. IPA determined groups of genes that
together constitute networks. Such networks indicate
how the genes and/or proteins of interest may influence
each other above and beyond canonical pathways that
are described in the Kyoto Encyclopedia of Genes and
Genomes (KEGG, www.genome.jp/kegg). The IPA gen-
erated networks are listed in a certain order, with the
top networks having a lower likelihood that the genera-
tion of the networks was serendipitous.
Additional material
Additional file 1: CGH data details. Detailed list of all chromosomal
imbalances of all endometrial tumors.
Additional file 2: Unique DEG list. List of differentially expressed genes
that were unique for all pair-wise group comparisons.
Additional file 3: Differential expressed protein lists. List of all
significant proteins of all pair-wise group comparisons.
Additional file 4: Involved genes in pathway analysis. Presentation of
all genes that are involved in identified pathways.
Additional file 5: Quality assessment criteria. Quality control criteria
for microarray values that had to be fulfilled for further analysis.
Additional file 6: Microarray data analysis (two-group class
comparison). Details of applied algorithms for microarray data analysis.
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